source
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.BioPharma Dive · 2mo ago↗ source
- A migraine drugmaker heads to the public markets through reverse mergerMentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.BioPharma Dive · 2mo ago↗ source
- STAT+: Dexcom CEO hints at future uses for CGMIn this edition of STAT Health Tech: Takeaways from a conversation with Dexcom CEO, and updates on WiSeR, and Epic's market share.STAT · 2mo ago